
FDA Pushes Out Decision for Cytokinetics Heart Drug to Review Proposed Safety Plan
Cytokinetics aims to compete with a Bristol Myers Squibb heart drug projected to become a blockbuster seller, and the company’s value proposition is that its drug candidate has a potential safety edge. The biotech needs to wait a little longer to see what …